<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124452">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02003573</url>
  </required_header>
  <id_info>
    <org_study_id>1230.30</org_study_id>
    <secondary_id>2013-001752-36</secondary_id>
    <nct_id>NCT02003573</nct_id>
  </id_info>
  <brief_title>Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients &gt;= 65 Years With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to investigate the maximum tolerated dose (MTD), safety and
      efficacy of volasertib in combination with decitabine in patients with acute myeloid
      leukaemia (AML)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidents of DLTs for volasertib in combination with decitabine</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission (CR)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission with incomplete blood count recovery (CRi)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapsed free survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>single arm (phase I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>volasertib + decitabine (phase II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open label, combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>decitabine (phase II)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open label, comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine iv</intervention_name>
    <description>decitabine iv fixed dose</description>
    <arm_group_label>single arm (phase I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>volasertib iv infusion</intervention_name>
    <description>volasertib iv infusion RP2D</description>
    <arm_group_label>volasertib + decitabine (phase II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>volasertib iv infusion</intervention_name>
    <description>volasertib iv infusion RP2D</description>
    <arm_group_label>single arm (phase I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine iv</intervention_name>
    <description>decitabine iv fixed dose</description>
    <arm_group_label>volasertib + decitabine (phase II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine iv</intervention_name>
    <description>decitabine iv fixed dose</description>
    <arm_group_label>decitabine (phase II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Phase I part:  Male or female elderly patients &gt;=60 years old with previously
             untreated or relapsed/refractory AML after one prior chemotherapy

          2. Phase IIa part:  Male or female elderly patients &gt;=60 years old with previously
             untreated AML

          3. Histologically or cytologically confirmed AML.

          4. Patient is eligible for decitabine treatment

          5. Eastern co-operative oncology group (ECOG) performance score &lt;=2 at screening

          6. Signed and dated written informed consent

        Exclusion criteria:

          1. Phase IIa: prior chemotherapy for AML

          2. Acute promyelocytic leukemia (FAB subtype M3)

          3. Second malignancy currently requiring active therapy

          4. Current clinical central nervous system (CNS) symptoms deemed by the investigator to
             be related to leukemic CNS involvement

          5. QTcF prolongation deemed clinically relevant by the investigator (e.g., QTcF &gt; 470
             ms, congenital long QT syndrome, etc.).

          6. Concomitant anti-leukemic treatment

          7. Concomitant anti-infective therapy which, in the opinion of the investigator, is
             considered relevant for the evaluation of the efficacy or safety of the trial drug

          8. Patients with a systemic fungal, bacterial, viral, or other infection not controlled

          9. Contraindications for decitabine treatment

         10. Treatment with any investigational drug within 2 weeks of administration of first
             study medication dose or within less than five half times of the investigational drug
             before treatment with the present trial drug and / or persistence of toxicities of
             prior anti-leukemic therapies

         11. Prior treatment with a Plk1 inhibitor such as volasertib  or treatment in a clinical
             trial using a Plk inhibitory compound
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1230.30.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1230.30.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1230.30.10005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1230.30.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1230.30.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
